Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
“People with diabetes are turning to mobile devices to help manage and track their condition,” said Dr. Partha Kar, Consultant in Diabetes and Endocrinology, Portsmouth Hospitals NHS Trust. “They want solutions that seamlessly integrate into their lives and present their readings in a simple and intuitive way. The CONTOUR®NEXT ONE system appears to be a development for interconnected diabetes management that has the potential to engage more people with diabetes in their treatment plans which could lead to better outcomes”.
“The launch of the CONTOUR®NEXT ONE blood glucose monitoring system in the United Kingdom is the latest of our high quality solutions designed to meet the needs of the diabetes community. By seamlessly capturing data from the meter in the app, this system has the potential to benefit people with diabetes by improving the understanding of their condition and helping them to make more informed decisions about managing their diabetes. We are delighted it is now available to help people with diabetes in the United Kingdom,” explained Ros Barker, Ascensia Diabetes Care.
The meter also includes additional features specifically designed to meet patient needs, including the smartLIGHTTM feature that gives instant feedback on blood glucose readings, for better understanding of results. It also has Second-Chance™ sampling, which prompts blood to be reapplied if there is not enough the first time, helping to avoid lancing for a second time and the wasting of strips.
“In the management of diabetes, the accuracy and quality of blood glucose data from an individual is crucial. The CONTOUR®NEXT ONE blood glucose meter has demonstrated consistently remarkable levels of accuracy and precision for patients. There is significant value for doctors and nurses by having easy access to this highly accurate data, which can help to improve how patients are managed,” added Ros.
Published study data has shown the CONTOUR®NEXT ONE meter to be remarkably accurate, exceeding EN ISO 15197:2015 accuracy criteria in both the laboratory and clinical setting. EN ISO 15197:2015 states that ≥95% of results must be within ± 0.83 mmol/L of the reference result for samples with blood glucose concentrations ˂5.56 mmol/L or ±15% for samples with blood glucose concentrations ≥5.56 mmol/L. Data in the clinical setting showed that 99.4% of readings from subject-obtained fingertip results exceeds EN ISO 15197:2015 accuracy criteria and 95% of readings were shown to be within ±0.47 mmol/L or ±8.4% of the YSI reference results.
An estimated 4 million people in United Kingdom have diabetes, according to Diabetes UK. The primary goal of diabetes management is to control blood sugar levels and ensure they are kept within a normal range. When blood glucose levels get too high (hypgerlycaemia) or too low (hypoglycaemia), it can lead to serious complications and, in severe cases, even death.
The launch of the CONTOUR®NEXT ONE BGMS in the United Kingdom follows CE Mark approval that was recently received, on 17 May 2016. As it is app based, the system is designed to evolve in the future, bringing new capabilities and features to help people with diabetes manage their condition.